Financial Performance - In 2024, the company's overall revenue decreased by 23.52%, with the medical device segment declining by 9.47% due to significant drops in the in vitro diagnostic business, while coronary intervention and structural heart disease segments grew by 6.35% and 44.03% respectively [2] - The pharmaceutical segment saw a substantial revenue decline, with raw material drug revenue down by 14.99% and formulation business revenue down by 46.50%, primarily due to the impact of the "Four Same" policy and price reductions from centralized procurement [2] - The medical services and health management segment's revenue fell by 19.24%, mainly due to decreased demand for blood oxygen products [2] - The company's net profit attributable to shareholders dropped by 80.37% in 2024, influenced by goodwill and specific asset impairment losses of 251 million [2] Operational Adjustments - The company reduced its workforce by 1,409 employees, focusing on optimizing R&D and marketing personnel in the diagnostic and pharmaceutical segments [2] - Marketing tasks are now allocated directly to individual sales representatives through digital management, enhancing operational efficiency [2] - The company has shut down subsidiaries that were consistently losing money and had unclear prospects [2] Future Outlook - For 2025, the company is cautiously optimistic, expecting a 30% year-on-year increase in pharmaceutical sales, projecting formulation business revenue around 1.8 billion [3] - The medical device segment is anticipated to grow by approximately 10%, with cardiovascular intervention business expected to increase by 10-15% [3] - The medical services and health management segment is projected to grow by 15%, driven by new business from hospitals [3] - The company plans to launch its first dermatological injection product by the end of Q2 2025, with another product expected to be approved mid-year [3] Profitability and Cost Management - The overall gross margin for the pharmaceutical segment has decreased by nearly 15 percentage points due to price reductions in key products [4] - The company aims to control sales expenses for new products to within 30% of planned sales costs, focusing on maintaining healthy cash flow [4] Market Dynamics - The impact of US-China trade tensions is minimal, with less than $10 million in OEM B2B orders, and potential opportunities for domestic product substitution due to tariffs [3][4] - The company anticipates a more moderate approach to centralized procurement, allowing broader participation in the market [4] Product Development and Strategy - The company is focusing on new product launches in structural heart, dermatology, and neuro-modulation sectors for future profit growth [5] - The TAVR product line is expected to see steady growth, with sales targets set at 200 million for the year, although achieving this remains uncertain [5] - The company is exploring opportunities in AI technology integration with hardware devices to enhance revenue streams [8]

Core Viewpoint - Lepu Medical reported a significant decline in financial performance for the year 2024, with a notable drop in revenue and net profit compared to the previous year [1][2]. Financial Performance Summary - The company's operating revenue for 2024 was 6.10 billion yuan, a decrease of 23.52% from 2023's 7.98 billion yuan [2]. - Net profit attributable to shareholders was 246.94 million yuan, down 80.37% from 1.26 billion yuan in 2023 [2]. - The net profit after deducting non-recurring gains and losses was 221.43 million yuan, reflecting an 80.28% decline from 1.12 billion yuan in the previous year [2]. - The net cash flow from operating activities was 734.64 million yuan, a decrease of 25.82% compared to 990.36 million yuan in 2023 [2]. Historical Comparison - In 2023, Lepu Medical's operating revenue was 7.98 billion yuan, down 24.78% from 2022 [3]. - The net profit attributable to shareholders in 2023 was 1.26 billion yuan, a decrease of 42.91% from 2022 [3]. - The net cash flow from operating activities in 2023 was 990.36 million yuan, down 64.51% from 2022 [3]. Profit Distribution Plan - The company approved a profit distribution plan, proposing a cash dividend of 1.35 yuan per 10 shares (including tax) to all shareholders, with no bonus shares [2].

乐普医疗 20250420 摘要 Q&A 公司在 2024 年和 2025 年一季度的财务表现如何？ 2024 年公司的整体营收下降，主要原因是诊断板块的收入减少。器械板块的营 收下降了 9%，其中心血管板块仍保持增长，增幅约为 10%。药品板块的降幅最 大，约为 40%，其中原料药降幅约 20%，制剂药品降幅约 42%。服务和医疗板块 也受到新冠疫情影响显著下降。总体来看，公司 2024 年的销售额降低了 20%， • 乐普医疗 2024 年销售额下降 20%，利润下降 80%，主要受原料药、制剂药 品及疫情影响，但 2025 年一季度收入和利润已明显回暖。公司通过裁员 1,600 人（含 400 研发人员）、优化营销策略、关闭亏损业务等措施应对 挑战。 • 公司预计 2025 年经营状况好转，药品销售额预计同比增长 30%左右，器械 增长 10%左右，主要来自心血管、外科及诊断领域。中美贸易脱钩可能带 来进口替代机会，利好公司发展。 • 公司现金流稳定，2023 年净现金流 9-10 亿元，2024 年 7 亿元。分红和股 票回购显示公司信心。对美国出口业务影响有限，但中美脱钩加速进口替 代，为起搏器等领 ...

证券研究报告 乐普医疗 (300003 CH) 1Q25 业绩环比改善，看好 25 年发展向上 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 20 日│中国内地 | 医疗器械 | 结构性心脏病业务表现亮眼，看好公司三大板块 25 年发展向上 1）器械：24 年/1Q25 收入 33.26/9.04 亿元（yoy-9.5%/+2.1%），其中结构 性心脏病业务在多款新品获批背景下表现亮眼， 24 年 /1Q25 收入 yoy+44.0%/+37.4%；看好板块收入25年重回稳健增长。2）药品：24年/1Q25 收入 17.58/5.95 亿元（yoy-42.3%/-25.0%），主因行业政策影响下终端进货 意愿降低，但目前零售渠道库存已基本清理完毕，1Q25 板块收入已边际明 显改善（qoq+111.4%），看好板块收入 25 年恢复稳健增长；3）医疗服务 及健康管理：24 年/1Q25 收入 10.19/2.38 亿元（yoy-19.2%/-2.4%），主因 板块发展策略调整；看好板块 25 年伴随新品上市实现向好发展。 产品矩阵 ...

Core Viewpoint - The company experienced a significant decline in revenue and net profit in 2024 due to macroeconomic conditions and industry policy impacts, but there are signs of recovery in 2025 with new product approvals and improved sales in various segments [1][2]. Group 1: Financial Performance - In 2024, the company reported revenue of 6.103 billion yuan, net profit attributable to shareholders of 247 million yuan, and net profit excluding non-recurring items of 221 million yuan, reflecting year-over-year declines of 23.5%, 80.4%, and 80.3% respectively [1]. - For Q1 2025, the company achieved revenue of 1.736 billion yuan, net profit attributable to shareholders of 379 million yuan, and net profit excluding non-recurring items of 337 million yuan, showing year-over-year declines of 9.7%, 21.4%, and 26.1% respectively, but with quarter-over-quarter improvements [1]. - The company expects a recovery in 2025 driven by new product approvals and a gradual restoration of its generic drug business [1]. Group 2: Business Segments - The structural heart disease segment showed strong performance with revenues of 3.326 billion yuan in 2024 and 904 million yuan in Q1 2025, marking year-over-year growth of 44.0% and 37.4% respectively [2]. - The pharmaceutical segment reported revenues of 1.758 billion yuan in 2024 and 595 million yuan in Q1 2025, with a year-over-year decline of 42.3% in 2024 but a significant quarter-over-quarter improvement of 111.4% in Q1 2025 [2]. - The medical services and health management segment generated revenues of 1.019 billion yuan in 2024 and 238 million yuan in Q1 2025, with year-over-year declines of 19.2% and 2.4% respectively, but is expected to improve with new product launches [2]. Group 3: Product Development - The company has expanded its product matrix, with several cardiovascular devices approved for market, including various catheter types and a biodegradable left atrial appendage occluder [3]. - In pharmaceuticals, the company is advancing its GLP-1 class products and has completed clinical trials for several key drugs, including a biosimilar for dulaglutide [3]. - Other product developments include continuous glucose monitoring systems and ongoing research in ophthalmology and dermatology [3]. Group 4: Profit Forecast and Valuation - The company anticipates net profits of 1.003 billion yuan, 1.156 billion yuan, and 1.331 billion yuan for 2025-2027, reflecting downward adjustments of 34% and 36% for 2025 and 2026 respectively [4]. - Given the diverse business layout and comprehensive sales channels, the company is assigned a 24x PE valuation for 2025, leading to a target price of 12.81 yuan [4].

Core Insights - Lepu Medical reported a revenue decline of 23.52% to 6.103 billion yuan and a net profit drop of 80.37% to 247 million yuan for the year 2024 [1] Group 1: Medical Device Segment - The medical device segment is the largest revenue-generating area for the company, with three main sub-segments: cardiovascular intervention, in vitro diagnostics, and surgical anesthesia [1] - The cardiovascular intervention segment generated revenue of 3.326 billion yuan, a decrease of 9.47% year-on-year, with coronary intervention revenue at 1.622 billion yuan, an increase of 6.35%, and structural heart disease revenue at 469 million yuan, an increase of 44.03% [1] - The surgical anesthesia business achieved revenue of 541 million yuan, a slight increase of 0.27% [1] Group 2: In Vitro Diagnostics and Pharmaceutical Segment - The in vitro diagnostics segment reported revenue of 333 million yuan, a significant decline of 51.31%, attributed to intensified competition and price reductions, with personnel and strategic adjustments causing some business fluctuations [2] - The pharmaceutical segment generated revenue of 1.758 billion yuan, down 42.25%, with formulations (generic drugs) at 1.409 billion yuan, a decrease of 46.50%, and raw materials at 349 million yuan, down 14.99% [2] - The company shifted its focus to OTC retail after core products were included in national procurement [2] Group 3: Medical Services and Health Management - The medical services and health management segment reported revenue of 1.019 billion yuan, a decline of 19.24%, while the Hefei Cardiovascular Hospital experienced significant growth, with revenue increasing by 15.60% under new leadership [2]

—— 2024 年年报及 2025 年一季报业绩点评 维持 程培 孟熙 | 市场数据 | 2025-04-18 | | --- | --- | | 股票代码 | 300003.SZ | | A 股收盘价(元) | 10.87 | | 上证指数 | 3276.73 | | 总股本(万股) | 188061.11 | | 实际流通 A 股(万股) | 161609.84 | | 流通 A 股市值(亿元) | 175.67 | ⚫ ⚫ ⚫ ⚫ · 医药行业 ⚫⚫ 公司点评报告 · 医药行业 E券|CGS 附录: 公司财务预测表 | 资产负债表(百万元) | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 流动资产 | 8436.28 | 10340.26 | 11453.76 | 12768.24 | | 现金 | 3718.02 | 5383.28 | 6291.37 | 7448.06 | | 应收账款 | 1530.66 | 1639.89 | 1720.60 | 1795.56 | | 其它应收款 | 114.40 | 12 ...

Core Viewpoint - Lepu Medical has experienced a significant decline in performance, with net profit plummeting over 80% in 2024, marking the worst performance since its listing in 2009 [1][3][6]. Financial Performance - In 2024, the company reported operating revenue of approximately 6.1 billion yuan, a decrease of 23.52% year-on-year [2][3]. - The net profit attributable to shareholders was about 246.94 million yuan, down 80.37% compared to the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was approximately 221.43 million yuan, reflecting an 80.28% decline [2][3]. - The net cash flow from operating activities was 734.64 million yuan, a decrease of 25.82% [2]. - Basic and diluted earnings per share were both 0.1336 yuan, down 80.23% [2]. - The total assets at the end of 2024 were approximately 24.57 billion yuan, a decrease of 1.80% from the previous year [2]. Business Segments - The medical device segment, the largest revenue contributor, generated 3.33 billion yuan, down 9.47% year-on-year [9]. - The pharmaceutical segment reported revenue of 1.76 billion yuan, a decline of 42.25%, with the generic drug revenue dropping 46.5% [9][10]. - The medical services and health management segment achieved revenue of 1.02 billion yuan, down 19.24% [11]. Asset Impairment - The company recorded impairment losses on goodwill and other specific assets totaling approximately 251 million yuan, impacting net profit by about 217 million yuan [6][8]. - High inventory impairment provisions were noted, with a total of about 168 million yuan, including 136 million yuan for testing products [7]. Strategic Adjustments - The company is dynamically adjusting its business strategies across segments to promote sustainable high-quality development [11]. - There is a strategic shift towards innovative drugs and skin injection products, while reducing investment in generic drugs [10][11].

心血管器械龙头企业乐普医疗（300003）(SZ300003)，已经连续两年营收、净利润双双下滑。 根据公司4月18日发布的年报，2024年公司营业收入61.03亿元，同比下降23.52%，归母净利润为2.47亿 元，同比下降80.37%。 去年，公司的医疗器械板块收入同比下滑，但这已不是最受伤的板块。公告显示，乐普医疗去年药品收 入同比减少42.25%。作为应对，公司决定战略性收缩仿制药业务投入，逐步将资源转向创新药及皮肤 科注射类产品的研发。战略性收缩仿制药业务投入 乐普医疗的收入、归母净利润"双降"是从2023年开始的。那年公司这两项财务指标的同比降幅分别为 24.78%和42.91%，收入规模最大的医疗器械板块收入同比减少37.50%。 到了2024年，乐普医疗的归母净利润同比降幅进一步扩大到80.37%。但医疗器械板块已经不再是营收 同比下降最多的业务了。 去年，国家医保局推动"四同药品"价格专项治理，院内医保药品价格向院外市场传导，非医保药品价格 同步承压，导致OTC(非处方药)终端销售受阻。在此背景下，乐普医疗零售端产品的纯销与发货量短期 内显著下滑。药品板块去年收入同比减少42.25%，这个降 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-031 乐普（北京）医疗器械股份有限公司 关于调整第六届董事会审计委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称"公司"）于2025年4月17 日召开第六届董事会第十四次会议，审议通过了《关于调整审计委员会委员的议 案》，同意对公司第六届董事会审计委员会部分委员进行调整。具体情况如下： 公司董事会推举独立董事甘亮先生担任第六届董事会审计委员会委员，任期 自本次董事会审议通过之日起至第六届董事会届满之日止。 调整后公司第六届董事会审计委员会委员为曲新女士（独立董事）、王立华 先生（独立董事）、甘亮先生（独立董事）三人，其中曲新女士为主任委员。 特此公告。 乐普（北京）医疗器械股份有限公司 董事会 二〇二五年四月十九日 1 ...